Iwona Hone
Head of Investor Relations
Replay available
Lineage Cell Therapeutics, Inc. (AMEX: LCTX) Q2 2025 earnings conference call, held 2025-08-12. Replay captured from the company's public earnings webcast.

Head of Investor Relations
Chief Executive Officer
Chief Financial Officer
Analyst, Beard Research
Analyst, H.C. Wainwright
Analyst, B. Riley Securities
Analyst, Maxim Group
Analyst, Raymond James
Watch the replay and follow the connected company analysis, news, and investor updates for Lineage Cell Therapeutics, Inc..
WEBVTT 00:00:00.031 -- 00:00:04.335 At this time, all participants are in a listen-only mode. 00:00:04.335 -- 00:00:09.521 An audio webcast of this call is available on the Investors section of Lineage 00:00:09.521 -- 00:00:13.042 website at www.lineagecell.com. 00:00:14.266 -- 00:00:19.511 This call is subject to copyright and is the property of lineage and recordings, 00:00:19.511 -- 00:00:24.816 reproductions, or transmissions of this call without the express written consent of lineage 00:00:24.816 -- 00:00:30.187 are strictly prohibited. As a reminder, today's call is being recorded. 00:00:30.187 -- 00:00:34.833 I would now like to introduce your host for today's call, Iwona Hone, Head of Investor 00:00:34.833 -- 00:00:38.778 Relations of Lineage. Ms. Hone, please go ahead. 00:00:38.778 -- 00:00:42.143 Thank you, Desiree. Good afternoon, and thank you for joining us. 00:00:42.143 -- 00:00:47.509 A press release reporting our second quarter 2025 financial results was issued earlier 00:00:47.509 -- 00:00:53.537 today, August 12, 2025, and can be found on the Investors section of our website. 00:00:53.537 -- 00:00:57.903 Please note that today's remarks and responses to your questions reflect management's 00:00:57.903 -- 00:01:02.524 views as of today only. and will contain forward looking statements within the meaning 00:01:02.524 -- 00:01:07.748 of federal securities laws. Statements made during this discussion that are not statements 00:01:07.748 -- 00:01:12.393 of historical fact should be considered forward looking statements, which are subject 00:01:12.393 -- 00:01:18.218 to significant risks and uncertainties. The company's actual results or performance 00:01:18.218 -- 00:01:23.863 may differ materially from the expectations indicated by such forward looking ...